Abstract | OBJECTIVE: METHODS: C57BL/6 mice were randomly assigned to a control (no EAE) group, or one of the four myelin oligodendrocyte glycoprotein-induced EAE groups: vehicle, lenalidomide, nanoceria, or lenalidomide plus nanoceria. During a 23 day period, clinical EAE symptoms were evaluated daily, and MRI brain scans were performed at 11-13 days and 20-22 days. Histological and biochemical analyses of brain tissue samples were performed to quantify myelin loss and local inflammation. RESULTS:
Lenalidomide treatment alone delayed symptom onset, while nanoceria treatment had no effect on symptom onset or severity, but did promote recovery; lenalidomide and nanoceria each significantly attenuated white matter pathology and associated inflammation. Combined treatment with lenalidomide and nanoceria resulted in a near elimination of EAE symptoms, and reduced white matter pathology and inflammatory cell responses to a much greater extent than either treatment alone. INTERPRETATION:
|
Authors | Erez Eitan, Emmette R Hutchison, Nigel H Greig, David Tweedie, Hasan Celik, Soumita Ghosh, Kenneth W Fishbein, Richard G Spencer, Carl Y Sasaki, Paritosh Ghosh, Soumen Das, Susheela Chigurapati, James Raymick, Sumit Sarkar, Srinivasulu Chigurupati, Sudipta Seal, Mark P Mattson |
Journal | Experimental neurology
(Exp Neurol)
Vol. 273
Pg. 151-60
(Nov 2015)
ISSN: 1090-2430 [Electronic] United States |
PMID | 26277686
(Publication Type: Journal Article, Research Support, N.I.H., Intramural)
|
Copyright | Published by Elsevier Inc. |
Chemical References |
- Cytokines
- Immunologic Factors
- RNA, Messenger
- Cerium
- Thalidomide
- ceric oxide
- Lenalidomide
|
Topics |
- Analysis of Variance
- Animals
- Autoimmunity
(drug effects)
- Cells, Cultured
- Central Nervous System
(drug effects, immunology, pathology)
- Cerium
(therapeutic use)
- Cytokines
(genetics, metabolism)
- Disease Models, Animal
- Encephalomyelitis, Autoimmune, Experimental
(drug therapy)
- Female
- Flow Cytometry
- Gene Expression Regulation
(drug effects)
- Immunologic Factors
(therapeutic use)
- Lenalidomide
- Magnetic Resonance Imaging
- Mice
- Mice, Inbred C57BL
- RNA, Messenger
- Thalidomide
(analogs & derivatives, therapeutic use)
- Time Factors
|